DK0717638T3 - Cyclodextriner til reduktion af den af cytotoksiske forbindelser forårsagede karekstravasation - Google Patents
Cyclodextriner til reduktion af den af cytotoksiske forbindelser forårsagede karekstravasationInfo
- Publication number
- DK0717638T3 DK0717638T3 DK94927983T DK94927983T DK0717638T3 DK 0717638 T3 DK0717638 T3 DK 0717638T3 DK 94927983 T DK94927983 T DK 94927983T DK 94927983 T DK94927983 T DK 94927983T DK 0717638 T3 DK0717638 T3 DK 0717638T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- cytotoxic
- cyclodextrin
- ulceration
- compound
- Prior art date
Links
- 231100000433 cytotoxic Toxicity 0.000 title abstract 5
- 230000001472 cytotoxic effect Effects 0.000 title abstract 5
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010047139 Vasoconstriction Diseases 0.000 title 1
- 229940097362 cyclodextrins Drugs 0.000 title 1
- 230000025033 vasoconstriction Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 7
- 208000025865 Ulcer Diseases 0.000 abstract 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 230000007794 irritation Effects 0.000 abstract 2
- 230000036269 ulceration Effects 0.000 abstract 2
- 206010015866 Extravasation Diseases 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- -1 cyclodextrin compound Chemical class 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 230000036251 extravasation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11672493A | 1993-09-03 | 1993-09-03 | |
| US08/297,249 US5602112A (en) | 1992-06-19 | 1994-08-26 | Pharmaceutical formulation |
| PCT/US1994/009879 WO1995006485A1 (fr) | 1993-09-03 | 1994-09-02 | Compositions pharmaceutiques ameliorees |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0717638T3 true DK0717638T3 (da) | 2002-07-01 |
Family
ID=26814548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94927983T DK0717638T3 (da) | 1993-09-03 | 1994-09-02 | Cyclodextriner til reduktion af den af cytotoksiske forbindelser forårsagede karekstravasation |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US5602112A (fr) |
| EP (1) | EP0717638B1 (fr) |
| JP (1) | JPH09502185A (fr) |
| AT (1) | ATE214290T1 (fr) |
| AU (1) | AU7718694A (fr) |
| CA (1) | CA2172159C (fr) |
| DE (1) | DE69430126T2 (fr) |
| DK (1) | DK0717638T3 (fr) |
| ES (1) | ES2171462T3 (fr) |
| HU (1) | HUT73778A (fr) |
| IL (1) | IL110825A0 (fr) |
| PT (1) | PT717638E (fr) |
| WO (1) | WO1995006485A1 (fr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| US20040014695A1 (en) * | 1992-06-19 | 2004-01-22 | Supergen, Inc. | Pharmaceutical formulation |
| EP0689438B1 (fr) * | 1993-03-26 | 2003-06-04 | Franciscus Wilhelmus Henricus Maria Merkus | Compositions pharmaceutiques pour l'administration intranasale d'apomorphine |
| AU737078C (en) | 1996-05-24 | 2002-05-02 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing diseases of body passageways |
| US6566353B2 (en) * | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
| NZ336381A (en) | 1996-12-30 | 2000-11-24 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
| HUP9701945A3 (en) * | 1997-11-10 | 2000-04-28 | Hexal Ag | Pharmaceutical composition for injection containing cyclodextrin and taxoids |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| GB9921958D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins |
| GB9921954D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| ES2316445T3 (es) * | 2000-05-02 | 2009-04-16 | Theravance, Inc. | Composicion que contiene una ciclodextrina y un antibiotico glicopeptidico. |
| WO2001083520A2 (fr) | 2000-05-02 | 2001-11-08 | Theravance,Inc | Derives polyacides de glycopeptides |
| US6872804B2 (en) * | 2000-06-22 | 2005-03-29 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
| AU2001259816A1 (en) | 2000-06-22 | 2002-01-02 | Advanced Medecine, Inc. | Polyhydroxy glycopeptide derivatives |
| WO2001098327A2 (fr) * | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Derives carboxy-saccharides de glycopeptides |
| UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| US6468989B1 (en) * | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| PE20020300A1 (es) * | 2000-08-22 | 2002-05-10 | Pharmacia Corp | Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco |
| IT1318689B1 (it) * | 2000-09-12 | 2003-08-27 | Pharmacia & Upjohn Spa | Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla |
| US6884885B2 (en) * | 2000-12-21 | 2005-04-26 | Cerestar Holding B.V. | Production of cyclodextrin complexes |
| EP1610751A4 (fr) * | 2001-04-26 | 2006-05-24 | Univ Texas | Compositions therapeutiques conjuguees agent/ligand, leur methodes de synthese et leur utilisation |
| US6528076B2 (en) | 2001-07-06 | 2003-03-04 | Magic Herb Corp. | Topical compositions and methods for treating pain |
| GB0127677D0 (en) * | 2001-11-19 | 2002-01-09 | Vianex S A | Inclusion complex |
| US7261875B2 (en) * | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
| US6828311B2 (en) | 2002-05-29 | 2004-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Formulation for the parenteral application of a sodium channel blocker |
| JP2006508917A (ja) * | 2002-09-05 | 2006-03-16 | ブハラット セルムズ アンド ヴァクシンズ リミテッド | メスナを有する、オキサザホスホリンの液体安定性組成物 |
| US7157446B2 (en) * | 2003-05-02 | 2007-01-02 | Bristol Myers Squibb Company | Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
| KR100834232B1 (ko) * | 2004-01-30 | 2008-05-30 | 화이자 프로덕츠 인크. | 액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제 |
| ES2347283T3 (es) * | 2005-10-14 | 2010-10-27 | Janssen Pharmaceutica N.V. | Formulaciones de tipifarnib para la aplicacion intravenosa. |
| CN100411688C (zh) * | 2006-09-12 | 2008-08-20 | 南京师范大学 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
| CN100486645C (zh) | 2006-09-12 | 2009-05-13 | 南京师范大学 | 含有环糊精紫杉醇包合物的药物组合物及其制备方法 |
| AU2007325576B2 (en) | 2006-10-20 | 2013-01-10 | Icos Corporation | Compositions of Chk1 inhibitors |
| WO2009132352A1 (fr) * | 2008-04-25 | 2009-10-29 | Rhode Island Hospital | Compositions actives pour écran solaire |
| MY161597A (en) | 2008-11-15 | 2017-04-28 | Rib-X Pharmaceuticals Inc | Antimicrobial compositions |
| RU2734236C2 (ru) * | 2009-02-25 | 2020-10-13 | Софткемо Фарма Корп. | Композиции бендамустина и циклополисахарида |
| CN102458114A (zh) | 2009-05-29 | 2012-05-16 | 锡德克斯药物公司 | 包含环糊精衍生物的可注射美法仑组合物及其制备和使用方法 |
| US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
| US8389558B2 (en) * | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
| US20110015245A1 (en) * | 2009-07-20 | 2011-01-20 | Valery Alakhov | Bendamustine amphiphilic cationic compositions |
| TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前－乳劑調配物及其製造與使用之方法 |
| SG10201503234SA (en) | 2010-05-03 | 2015-06-29 | Teikoku Pharma Usa Inc | Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| EA028413B1 (ru) * | 2011-09-18 | 2017-11-30 | Эро-Селтик С.А. | Фармацевтические композиции |
| AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| CA2919837A1 (fr) * | 2013-08-02 | 2015-02-05 | Children's Hospital Medical Center | Compositions et methodes de traitement d'etats pathologiques associes a des lymphocytes t et/ou a des lymphocytes b actives |
| WO2015061206A2 (fr) | 2013-10-21 | 2015-04-30 | North Carolina State University | Procédés et produits de recombinaison pour administration d'un composé |
| RU2587716C2 (ru) * | 2014-01-14 | 2016-06-20 | Борис Игоревич Круглый | Стабильный фармацевтический состав на основе актиномицина д для инъекций |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| WO2020128913A1 (fr) | 2018-12-18 | 2020-06-25 | Mundipharma International Corporation Limited | Composés pour traiter un myélome multiple |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5735189B2 (fr) * | 1972-01-06 | 1982-07-27 | ||
| US4024223A (en) * | 1972-11-11 | 1977-05-17 | Teijin Limited | Stripe composition and method of reducing smell associated therewith |
| JPS53136513A (en) * | 1977-05-06 | 1978-11-29 | Ono Pharmaceut Co Ltd | Stabilization of prostaglandin-x-related compounds |
| HU176215B (en) * | 1978-01-27 | 1981-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1 |
| JPS54115368A (en) * | 1978-03-01 | 1979-09-07 | Ono Pharmaceut Co Ltd | Prostaglandin i2 analog, its preparation, and drug composition containing it as active constituent |
| DE2912409A1 (de) * | 1978-03-31 | 1979-10-11 | Ono Pharmaceutical Co | 6,9-methano-pgi tief 2 -analoge |
| US4352793A (en) * | 1979-04-26 | 1982-10-05 | Sumitomo Chemical Company, Limited | Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin |
| JPS6033430B2 (ja) * | 1980-05-12 | 1985-08-02 | 小野薬品工業株式会社 | プロスタグランジン類似化合物 |
| DE3270055D1 (en) * | 1981-01-23 | 1986-04-30 | Wellcome Found | Chemical complex |
| JPS5813541A (ja) * | 1981-07-16 | 1983-01-26 | Kureha Chem Ind Co Ltd | エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物 |
| US4407795A (en) * | 1981-07-16 | 1983-10-04 | American Cyanamid Company | Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use |
| JPS5838250A (ja) * | 1981-09-01 | 1983-03-05 | Teikoku Chem Ind Corp Ltd | 複合体 |
| JPS58126810A (ja) * | 1981-12-24 | 1983-07-28 | Kaken Pharmaceut Co Ltd | 抗炎症眼科用液剤およびその製法 |
| US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| JPS58177949A (ja) * | 1982-04-12 | 1983-10-18 | Takeda Chem Ind Ltd | ランカシジン群抗生物質包接化合物 |
| US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
| DE3315356A1 (de) * | 1982-04-30 | 1983-11-17 | Ono Pharmaceutical Co. Ltd., Osaka | Verwendung von prostaglandinanalogen |
| US4425336A (en) * | 1982-05-24 | 1984-01-10 | Key Pharmaceuticals, Inc. | 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes |
| US4424209A (en) * | 1982-06-21 | 1984-01-03 | Key Pharmaceuticals, Inc. | 3,4-Di-isobutyryloxy-N- 3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phenethylamine cyclodextrin complexes |
| JPS5910510A (ja) * | 1982-07-08 | 1984-01-20 | Nippon Zenyaku Kogyo Kk | 低刺激性チアムリン注射剤 |
| JPS5920230A (ja) * | 1982-07-19 | 1984-02-01 | チバ−ガイギ−・アクチエンゲゼルシヤフト | ピルプロフエン含有薬剤 |
| HU190818B (en) * | 1982-11-09 | 1986-11-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for producing complexes of piperonyl-butoxide-cyclodextrin |
| JPS6025967A (ja) * | 1983-07-21 | 1985-02-08 | Eisai Co Ltd | トリパミド包接化合物 |
| US4751095A (en) * | 1983-07-28 | 1988-06-14 | Karl Curtis L | Aspartame stabilization with cyclodextrin |
| JPS6081166A (ja) * | 1983-10-11 | 1985-05-09 | Fujisawa Pharmaceut Co Ltd | ２−ニトロオキシメチル−６−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法 |
| IT1196033B (it) * | 1984-02-22 | 1988-11-10 | Chiesi Farma Spa | Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche |
| US4675395A (en) * | 1984-03-14 | 1987-06-23 | Seiwa Technological Laboratories Limited | Cyclodextrin inclusion compound and process for its preparation |
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| JPS61207380A (ja) * | 1985-03-11 | 1986-09-13 | Taiyo Yakuhin Kogyo Kk | モベンゾキサミンの経口製剤 |
| JPS61286318A (ja) * | 1985-06-13 | 1986-12-16 | Ichiro Shibauchi | 浴剤の製造方法 |
| US4663316A (en) * | 1985-06-28 | 1987-05-05 | Warner-Lambert Company | Antibiotic clathrates and pharmaceutical compositions thereof |
| US4728509A (en) * | 1985-08-19 | 1988-03-01 | Takeda Chemical Industries, Ltd. | Aqueous liquid preparation |
| US4623641A (en) * | 1985-09-09 | 1986-11-18 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| EP0519428B1 (fr) * | 1991-06-21 | 2000-09-20 | Takeda Chemical Industries, Ltd. | Compositions de cyclodextrine contenant des dérivés de fumagillol |
| JP3176716B2 (ja) * | 1991-06-21 | 2001-06-18 | 武田薬品工業株式会社 | 溶解性が向上した難水溶性薬物組成物 |
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| JPH06157330A (ja) * | 1992-11-27 | 1994-06-03 | Ensuiko Sugar Refining Co Ltd | タキソールのサイクロデキストリン包接物，その製造法と用途 |
-
1994
- 1994-08-26 US US08/297,249 patent/US5602112A/en not_active Expired - Lifetime
- 1994-08-30 IL IL11082594A patent/IL110825A0/xx unknown
- 1994-09-02 AT AT94927983T patent/ATE214290T1/de active
- 1994-09-02 ES ES94927983T patent/ES2171462T3/es not_active Expired - Lifetime
- 1994-09-02 CA CA002172159A patent/CA2172159C/fr not_active Expired - Fee Related
- 1994-09-02 DK DK94927983T patent/DK0717638T3/da active
- 1994-09-02 AU AU77186/94A patent/AU7718694A/en not_active Abandoned
- 1994-09-02 HU HU9600612A patent/HUT73778A/hu unknown
- 1994-09-02 PT PT94927983T patent/PT717638E/pt unknown
- 1994-09-02 EP EP94927983A patent/EP0717638B1/fr not_active Expired - Lifetime
- 1994-09-02 WO PCT/US1994/009879 patent/WO1995006485A1/fr not_active Ceased
- 1994-09-02 JP JP7508268A patent/JPH09502185A/ja active Pending
- 1994-09-02 DE DE69430126T patent/DE69430126T2/de not_active Expired - Fee Related
-
1997
- 1997-02-03 US US08/790,223 patent/US5804568A/en not_active Expired - Lifetime
-
1998
- 1998-08-28 US US09/143,412 patent/US6048845A/en not_active Expired - Lifetime
-
1999
- 1999-07-02 US US09/347,096 patent/US6218374B1/en not_active Expired - Fee Related
-
2000
- 2000-10-05 US US09/684,375 patent/US6284747B1/en not_active Expired - Fee Related
-
2001
- 2001-08-23 US US09/938,473 patent/US6583125B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2171462T3 (es) | 2002-09-16 |
| WO1995006485A1 (fr) | 1995-03-09 |
| EP0717638B1 (fr) | 2002-03-13 |
| CA2172159A1 (fr) | 1995-03-09 |
| US20020058634A1 (en) | 2002-05-16 |
| IL110825A0 (en) | 1995-05-26 |
| PT717638E (pt) | 2002-07-31 |
| HUT73778A (en) | 1996-09-30 |
| AU7718694A (en) | 1995-03-22 |
| US6218374B1 (en) | 2001-04-17 |
| DE69430126T2 (de) | 2002-08-01 |
| EP0717638A1 (fr) | 1996-06-26 |
| ATE214290T1 (de) | 2002-03-15 |
| US6284747B1 (en) | 2001-09-04 |
| HU9600612D0 (en) | 1996-05-28 |
| US6048845A (en) | 2000-04-11 |
| JPH09502185A (ja) | 1997-03-04 |
| US6583125B2 (en) | 2003-06-24 |
| US5602112A (en) | 1997-02-11 |
| US5804568A (en) | 1998-09-08 |
| DE69430126D1 (de) | 2002-04-18 |
| CA2172159C (fr) | 2003-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0717638T3 (da) | Cyclodextriner til reduktion af den af cytotoksiske forbindelser forårsagede karekstravasation | |
| CZ289570B6 (cs) | Farmaceutické formulace obsahující vorikonazol | |
| ATE87319T1 (de) | Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate. | |
| WO2001072721A3 (fr) | Methodes et compositions synergetiques destinees au traitement du cancer | |
| MX9300141A (es) | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. | |
| EA199901014A1 (ru) | C-4"-замещенные макролидные производные | |
| WO2005063745A3 (fr) | Nouveaux composes de spiroindoline ou de spiroisoquinoline, methodes d'utilisation et compositions associees | |
| WO2002074200B1 (fr) | Preparation contenant du propofol et de la cyclodextrine d'ether sulfoalkylique | |
| FR2708608B1 (fr) | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. | |
| FR2714378B1 (fr) | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. | |
| KR950702994A (ko) | 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol) | |
| BR0111126A (pt) | Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos | |
| EE200200207A (et) | Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid | |
| NO941276D0 (no) | Lipofile, oligosakkaride antibiotikasaltpreparater | |
| WO1999012532A3 (fr) | Derives de piperidine contre la malaria | |
| WO1992019211A3 (fr) | Imidazobenzoquinones et composition contenant ces dernieres permettant de prevenir ou de traiter l'hypertension ou l'insuffisance cardiaque | |
| ATE356637T1 (de) | Supramolekulare komplexe enthaltende arzneimittel | |
| DE69212331D1 (de) | Imidazole derivate und diese enthaltende arzneimittel | |
| WO1996023771A3 (fr) | Inhibiteurs de l'agregation plaquettaire | |
| KR940702726A (ko) | 치환된 퀴놀린-3-카르복시아미드 화합물의 용도 및 이를 이용한 다발성 경화증의 치료방법 | |
| HUP0301247A2 (hu) | Antitumor terápia disztamicin származékokkal | |
| AU707220B2 (en) | Pharmaceutical composition for parenteral application containing an indole-carboxylic acid | |
| WO1999057125A3 (fr) | Derives d'hygromycine a | |
| KR20080055804A (ko) | 프로포폴을 포함하는 수성 마취 조성물 | |
| AU626480B2 (en) | Pharmaceutical preparations |